Insulet: Competing with its own insulin control algorithm
Insulet is developing the Omnipod Horizon hybrid closed-loop system, and in February touted data from the 1st feasibility study of the device. Data from the trial indicated that the device’s insulin control algorithm met safety requirements and was able to perform well with minimal incidents of hypoglycemia.
The Billerica, Mass.–based company enrolled 24 patients with type 1 diabetes in the 36-hour study. The feasibility trial used a modified version of Insulet’s Omnipod, a Dexcom continuous glucose monitor and Insulet’s personalized model predictive control algorithm..
Use of the system was associated with significantly less time spent in hypoglycemic blood glucose range, Insulet reported, compared to ranges prior to the study. The study showed that patients hit the target blood glucose control range 69% of the time over the course of the 36 hours and maintained target blood glucose control 90% of the time overnight.
Last year, Insulet inked an initial deal with diabetes developer Mode Automated Glucose Control to develop an artificial pancreas using its flagship OmniPod device.
The deal put into motion the integration of the Mode AGC algorithm into the OmniPod glucose management system, the company said. The algorithm, co-developed by Insulet medical director Dr. Howard Zisser, Francis Doyle and Eval Dassau at UC Santa Barbara, is being studied in a feasibility trial using an OmniPod prototype and a Dexcom continuous glucose monitor.